-
公开(公告)号：EP3412285A2
公开(公告)日：2018-12-12
申请号：EP18179582.4
申请日：2013-05-29
发明人： Gorath, Michaela
IPC分类号： A61K31/21 , A61K31/295 , A61K31/34 , A61K31/455 , A61K31/5377 , A61K33/00 , A61P9/00
CPC分类号： A61K31/21 , A61K31/295 , A61K31/34 , A61K31/455 , A61K31/5377 , A61K33/00
摘要： The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition.
-
公开(公告)号：EP2767279B1
公开(公告)日：2018-12-12
申请号：EP12839684.3
申请日：2012-10-05
IPC分类号： A61K31/197 , A61K31/28 , A61K33/06 , A61K33/26 , A61K33/30 , A61P7/06 , A61P13/12 , A61K31/295
CPC分类号： C07C217/08 , A61K31/195 , A61K31/197 , A61K31/221 , A61K31/28 , A61K31/295 , A61K33/06 , A61K33/26 , A61K33/30 , A61K45/06
摘要： Problem to be Solved The present invention provides a therapeutic agent and/or prophylactic agent for renal anemia. The present invention also provides an erythropoietin production promoter. Solution The present invention provides a therapeutic and/or prophylactic agent for renal anemia comprising ALAs. The present invention also provides an erythropoietin production promoter comprising ALAs.
-
3.发明授权
公开(公告)号：EP1978808B1
公开(公告)日：2018-08-29
申请号：EP07762833.7
申请日：2007-01-26
发明人： CHAN, Keith , TOWN, Winston , CHIANG, Shou Shan
CPC分类号： A61K31/295 , A61K9/143 , A61K31/555 , A61K33/26
摘要： The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.
-
公开(公告)号：EP3216782A4
公开(公告)日：2018-07-18
申请号：EP15856332
申请日：2015-11-05
IPC分类号： C07C229/76 , A61K31/295 , A61P3/02 , A61P7/06 , C07C59/08 , C07C59/245 , C07C59/255 , C07C59/265 , C07C229/08 , C07C229/24 , C07C321/14 , C07D207/16
CPC分类号： A61K31/295 , C07C59/08 , C07C59/245 , C07C59/255 , C07C59/265 , C07C229/08 , C07C229/24 , C07C229/76 , C07C321/14 , C07D207/16
摘要： The invention describes hydrosoluble iron(III) oxyhydroxide complexes prepared from different sources of iron, amino acids and carboxylic acids and pharmaceuticals or food compositions containing them. The iron(III) complexes have no undesirable residual taste and can be used as supplementation forms for the prevention or treatment in anemia by iron deficiency in humans or animals.
-
公开(公告)号：EP3199152A4
公开(公告)日：2018-04-11
申请号：EP14902283
申请日：2014-09-26
申请人： IHI CORP , ISHIKAWA YOSHIHIRO
发明人： ISHIKAWA YOSHIHIRO , EGUCHI HARUKI
IPC分类号： A61K31/295 , A61K31/337 , A61P35/00
CPC分类号： C07F15/025 , A61K31/28 , A61K31/295 , A61K31/337 , A61K33/00 , A61K33/04 , A61K33/24 , A61K33/32
摘要： [Object] An anticancer agent capable of continuously killing cancer cells in a plurality of phases is provided. [Solution] An anticancer agent contains a complex produced by making a metal-salen complex compound, which includes a central metal and (N, N, O, O) as a quadridentate ligand and is magnetic, bind to taxane molecules which are anticancerous; and the anticancer agent is to kill cancer cells regarding which phase transition of its cell cycle occurs between phases including Gap1, Synthesis, Gap2, and Mitosis and Cytokinesis. The present invention is suited for use to kill cancer cells of breast cancer and, particularly, cancer cells of triple-negative breast cancer. The present invention is designed to make the anticancer agent contact the cancer cells in two or more continuous phases selected from a group consisting of Gap1, Synthesis, Gap2, and Mitosis and Cytokinesis and kill the cancer cells.
-
公开(公告)号：EP2135613B1
公开(公告)日：2017-11-22
申请号：EP08739088.6
申请日：2008-03-27
发明人： KUROIWA, Toshihiko , KAJIMOTO, Yoshinaga , MASUBUCHI, Takahiro , ISHIZUKA, Masahiro , TANAKA, Tohru
IPC分类号： A61K31/197 , A61K31/198 , A61K31/295 , A61K33/26 , A61K49/00 , A61P9/00 , A61P9/10 , A61P21/00 , A61P25/00 , A61P25/06 , A61P25/16 , A61P25/24 , A61P25/28
CPC分类号： A61K31/295 , A61K31/197 , A61K31/198 , A61K33/26 , A61K45/06 , A61K49/0008 , A61K2300/00
摘要： To provide a diagnostic agent for mitochondrial dysfunction brain diseases including cerebral infarction as a representative. A diagnostic agent for a mitochondrial dysfunction brain disease, which comprises (A) ´-aminolevulinic acid represented by the formula (1), a derivative thereof, or a salt thereof and (B) an iron compound in combination. €ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ R 2 R 1 NCH 2 COCH 2 CH 2 COR 3 €ƒ€ƒ€ƒ€ƒ€ƒ(1) wherein R 1 and R 2 each independently represents a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; and R 3 represents a hydroxy group, an alkoxy group, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino group.
-
公开(公告)号：EP3199152A1
公开(公告)日：2017-08-02
申请号：EP14902283.2
申请日：2014-09-26
IPC分类号： A61K31/295 , A61K31/337 , A61P35/00
CPC分类号： C07F15/025 , A61K31/28 , A61K31/295 , A61K31/337 , A61K33/00 , A61K33/04 , A61K33/24 , A61K33/32
摘要： [Object] An anticancer agent capable of continuously killing cancer cells in a plurality of phases is provided.
[Solution] An anticancer agent contains a complex produced by making a metal-salen complex compound, which includes a central metal and (N, N, O, O) as a quadridentate ligand and is magnetic, bind to taxane molecules which are anticancerous; and the anticancer agent is to kill cancer cells regarding which phase transition of its cell cycle occurs between phases including Gap1, Synthesis, Gap2, and Mitosis and Cytokinesis. The present invention is suited for use to kill cancer cells of breast cancer and, particularly, cancer cells of triple-negative breast cancer. The present invention is designed to make the anticancer agent contact the cancer cells in two or more continuous phases selected from a group consisting of Gap1, Synthesis, Gap2, and Mitosis and Cytokinesis and kill the cancer cells.摘要翻译： 本发明提供了能够连续杀死多个阶段的癌细胞的抗癌剂。 [解决方案]抗癌剂含有通过制备包含中心金属和（N，N，O，O）作为四齿配体且具有磁性的金属沙仑配合物化合物产生的复合物，其与抗癌的紫杉烷分子结合; 并且抗癌剂是杀死癌细胞，其细胞周期的哪个阶段发生在包括Gap1，合成，Gap2和有丝分裂和细胞分裂的阶段之间。 本发明适用于杀死乳癌的癌细胞，特别是三阴乳腺癌的癌细胞。 本发明旨在使抗癌剂在选自Gap1，合成，Gap2和有丝分裂和细胞分裂的两个或更多个连续相中与癌细胞接触并杀死癌细胞。
-
公开(公告)号：EP2745838B1
公开(公告)日：2017-07-26
申请号：EP12824258.3
申请日：2012-08-10
发明人： KINOSHITA, Kosaku , TANJOH, Katsuhisa , NODA, Akihiro , SAKURAI, Atsushi , TANAKA, Tohru , TAKAHASHI, Kiwamu , NAKAJIMA, Motowo , ABE, Fuminori
IPC分类号： A61K31/197 , A61K31/28 , A61K31/295 , A61K33/06 , A61K33/26 , A61K33/30 , A61K33/34 , A61P31/04 , A61P43/00
CPC分类号： A61K33/26 , A61K31/197 , A61K31/28 , A61K31/295 , A61K45/06
-
公开(公告)号：EP3191219A1
公开(公告)日：2017-07-19
申请号：EP15784157.8
申请日：2015-09-09
申请人： Lupin Limited
发明人： KUMAR, Gaurav , YADAV, Ashok, Sopan , AMRUTKAR, Nitesh Yashwant , ARORA, Surinder, Kumar , SHIVDAVKAR, Radhakrishna , RAY, Purna, Chandra , SINGH, Girij, Pal
IPC分类号： B01J20/28 , B01J20/24 , B01J20/06 , A61K31/295 , A61K33/26
CPC分类号： B01J20/06 , A61K31/295 , A61K33/26 , B01J20/043 , B01J20/24 , B01J20/28004 , B01J20/28059
摘要： The present invention is directed towards a manufacturing method for an iron containing phosphate adsorbent. Said iron containing phosphate adsorbent is characterized by a PSD d(0.9) in the range of 20 μm to 80 μm, a BET active surface area less than 15 m2/gm and phosphate binding in the range of 35 to 60 mg/gm.
摘要翻译： 本发明涉及一种含铁吸附剂的制造方法。 所述含铁吸附剂的特征在于20μm至80μm范围内的PSD d（0.9），小于15m 2 / g的BET活性表面积和35至60mg / g范围内的磷酸盐结合。
-
公开(公告)号：EP2164496B1
公开(公告)日：2017-04-12
申请号：EP08758648.3
申请日：2008-05-21
CPC分类号： A61K31/635 , A61K9/0095 , A61K31/295 , A61K31/53 , A61K31/7135 , A61K33/26 , A61K45/06 , A61K47/10 , A61K47/12 , A61K47/36 , A61K2300/00
-
-
-
-
-
-
-
-
-
搜索结果
391 条记录 (耗时 0.024 秒)
